logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
I

Ian D. Davis

monash university
H指数:76
被引数:2.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Cost-effectiveness of adding enzalutamide vs standard non-steroidal antiandrogen drugs for patients with metastatic hormone-sensitive prostate cancer undergoing standard first-line therapy: a within-trial, secondary end-point analysis of the ENZAMET phase 3, international randomized trial (ANZUP 1304)

在标准一线治疗基础上加用恩扎卢胺与标准非甾体抗雄激素药物用于转移性激素敏感前列腺癌患者的成本效益分析：ENZAMET III期国际随机试验（ANZUP 1304）的试验内、次要终点分析

EClinicalMedicine
IF10
2026-10-050
OAAI
Chi Kin Law; Martin R. Stockler; Andrew J. Martin; Ian D. Davis; Christopher J. Sweeney; Rachael L. Morton
Correction to: Prevalence of meeting aerobic physical activity and resistance training guidelines in advanced prostate cancer: a descriptive study of racial and regional disparities in the IRONMAN registry

更正：在IRONMAN登记研究中，满足有氧运动和抗阻训练指南的晚期前列腺癌患者患病率：种族和地区差异的描述性研究

Supportive Care in Cancer
IF3
2026-10-020
OAAI
Aleksander Solberg; May Grydeland; Tormod S. Nilsen; Anne H. Storås; Ian D. Davis; Natalie Greaves; Simon Anderson; Andre P. Fay; Kim N. Chi; Deborah Enting; Raymond McDermott; Simone Badal; Charles G. Waihenya; Ademola Popoola; John M. Lazarus; Joaquin Mateo; Anders Bjartell; Aurelius Omlin; Folakemi Odedina; Camille Ragin; Lorelei A. Mucci; Kjell M. Russnes
Insulin-Like Growth Factor Axis and Survival in Metastatic Hormone-Sensitive Prostate Cancer: Post-Hoc Analysis From the ENZAMET Phase 3 Trial

胰岛素样生长因子轴与转移性激素敏感型前列腺癌的生存：来自ENZAMET III期试验的事后分析

Prostate
IF2.5
2026-09-300
OAAI
Michael A. Cilento; Hui-Ming Lin; Nicole Yeung; Rachel M.N. Kim; Neil Portman; Martin R. Stockler; Andrew J. Martin; Vinod Subhash; Sonia Yip; Lisa M. Butler; Ian C. Marschner; Peter J. Meikle; Arun A. Azad; Ian D. Davis; Lisa G. Horvath; Christopher J. Sweeney
Predictive value of early PSMA upregulation for the response to enzalutamide ± 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial

早期PSMA上调对恩扎卢胺±177Lu-PSMA-617治疗高危转移性去势抵抗性前列腺癌疗效的预测价值：随机II期ENZA-p试验的亚组研究

Nature Cancer
IF28.5
2026-04-010
PRE
Emmett, Louise; Swiha, Mina; Papa, Nathan; Subramaniam, Shalini; Crumbaker, Megan; Joshua, Anthony; Nguyen, Andrew; Weickhardt, Andrew; Lee, Sze-Ting; Ng, Siobhan; Francis, Roslyn; Goh, Jeffrey; Pattison, David; Pathmanandavel, Sarennya; Hope, Thomas; Ayati, Narjess; Hofman, Michael; Sandhu, Shahneen; Niu, Claire; Martin, Andrew; Thomas, Hayley; Stockler, Martin; Davis, Ian
Attrition Rates in Metastatic Renal Cell Carcinoma (mRCC) Following First Line Immunotherapy-Based Treatment: Results From the International mRCC Database Consortium (IMDC)

在接受基于免疫治疗的一线治疗后转移性肾细胞癌（mRCC）中的患者流失率：来自国际mRCC数据库联盟（IMDC）的结果

Clinical Genitourinary Cancer
IF2.7
2026-01-010
PRE
Lemelin, Audreylie; Zarba, Martin; Takemura, Kosuke; Wells, J. Connor; Chehade, Razane El Hajj; Donskov, Frede; Porta, Camillo; De Velasco, Guillermo; Davis, Ian D.; Wood, Lori A.; Pal, Sumanta K.; Hansen, Aaron R.; Tran, Ben; Bjarnason, Georg A.; Li, Haoran; Kanesvaran, Ravindran; Powles, Thomas; Mckay, Rana R.; Choueiri, Toni K.; Heng, Daniel Y. C.
Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer

早期对转移性激素敏感型前列腺癌的 prostate-specific antigen (PSA) 阳性反应预测

Nature Communications
IF15.7
2025-12-170
OAAI
Soumyajit Roy; Yilun Sun; Maha Hussain; Kim N. Chi; Karim Fizazi; Ian D. Davis; Susan Halabi; Neeraj Agarwal; Simon Chowdhury; Bertrand Tombal; Scott C. Morgan; Shawn Malone; Pedro C. Barata; Michael Ong; Christopher J. D. Wallis; Alejandro Berlin; Umang Swami; Amar U. Kishan; Angela Y. Jia; Nicholas G. Zaorsky; Jorge A. Garcia; Prateek Mendiratta; Jason R. Brown; Vinod V. Subhash; Martin R. Stockler; Hayley Thomas; Rana R. McKay; Eric J. Small; Neal D. Shore; Fred Saad; Christopher J. Sweeney; Daniel E. Spratt
A roadmap for future clinical research in advanced prostate cancer: Findings from the Advanced Prostate Cancer Consensus Conference (APCCC) 2024

未来晚期前列腺癌临床研究的路线图：2024年晚期前列腺癌共识会议（APCCC）的研究结果

European Journal of Cancer
IF7.1
2025-11-210
PRE
Ursula M. Vogl; Sara Merler; Antonio Angrisani; Fabio Turco; Ian D. Davis; Jason A. Efstathiou; Karim Fizazi; Nicholas D. James; Neal Shore; Eric J. Small; Matthew R. Smith; Christopher J. Sweeney; Bertrand Tombal; Thomas Zilli; Ken Herrmann; Aurelius Omlin; Silke Gillessen
Tumour-based epigenetic signatures as markers of prostate cancer aggressiveness after radical prostatectomy

基于肿瘤的表观遗传学特征作为根治性前列腺切除术后前列腺癌侵袭性的标志物

British Journal of Cancer
IF6.8
2025-11-200
PRE
Yiyue Zhu; Elaheh Zarean; Danmeng L. Li; Robert L. O’Reilly; Ian D. Davis; Renea A. Taylor; Arun A. Azad; Damien M. Bolton; Nathan Papa; Nathan Lawrentschuk; Robert J. MacInnis; Roger L. Milne; Graham G. Giles; Melissa C. Southey; Pierre-Antoine Dugué
Comparative Survival in Metastatic Hormone-sensitive Prostate Cancer by Volume of Disease and Timing of Metastasis: A Living Network Meta-analysis

比较性生存分析：激素敏感性转移性前列腺癌按疾病体积和转移时间划分——一项动态网络Meta分析

European Urology
IF25.2
2025-11-040
PRE
Irbaz Bin Riaz; Syed Arsalan Ahmed Naqvi; Kunwer Sufyan Faisal; Huan He; Kaneez Zahra Rubab Khakwani; Daniel S. Childs; Jacob J. Orme; Praful Ravi; Parminder Singh; Syed A. Hussain; Kim Chi; Neeraj Agarwal; Axel S. Merseburger; Ian D. Davis; Andrew Armstrong; Maha H. Hussain; Matthew Smith; Gerhardt Attard; Bertrand Tombal; Karim Fizazi; Nick James; Aurelius Omlin; Silke Gillessen; Mohammad Hassan Murad; Eliezer M. Van Allen; Christopher J. Sweeney; Alan Haruo Bryce
Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial

基线PSMA-PET总肿瘤体积和SUVmean在转移性去势抵抗性前列腺癌中的预后和预测价值：一项来自多中心、开放标签、随机、II期试验ENZA-p (ANZUP1901)的亚研究

lancet oncology
IF0
2025-07-300
PRE
Louise Emmett; Nathan Papa; Shalini Subramaniam; Megan Crumbaker; Andrew Nguyen; Anthony M Joshua; Shahneen Sandhu; Andrew Weickhardt; Sze-Ting Lee; Siobhan Ng; Roslyn J Francis; Jeffrey C Goh; David A Pattison; Thean Hsiang Tan; Ian D Kirkwood; Narjess Ayati; Claire Niu; Michael S Hofman; Andrew James Martin; Hayley Thomas; Ian D Davis; Martin R Stockler
Lutetium-177–PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial

Lutetium-177-PSMA-617或cabazitaxel在转移性前列腺癌中的应用：随机II期therap试验的循环肿瘤DNA分析

Nature Medicine
IF50
2025-05-270
PRE
Edmond M. Kwan; Sarah W. S. Ng; Sofie H. Tolmeijer; Louise Emmett; Shahneen Sandhu; James P. Buteau; Amir Iravani; Anthony M. Joshua; Roslyn J. Francis; Vinod Subhash; Sze-Ting Lee; Andrew M. Scott; Andrew J. Martin; Martin R. Stockler; Gráinne Donnellan; Matti Annala; Cameron Herberts; Ian D. Davis; Michael S. Hofman; Arun A. Azad; Alexander W. Wyatt
Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post hoc analysis of the ENZAMET phase III randomised trial (ANZUP 1304)

循环脂质面板PCPro与转移性激素敏感前列腺癌临床结局的关联：ENZAMET III期随机试验（ANZUP 1304）的事后分析

Annals of Oncology
IF65.4
2025-05-200
PRE
H.-M. Lin; T. Scheinberg; N. Portman; R.M.N. Kim; R. Mellor; K. Huynh; A.N. Faulkner; N.A. Mellett; I.D. Davis; A. Martin; D. Sullivan; A. Joshua; M. McJannett; V. Subhash; S. Yip; A.A. Azad; I.C. Marschner; S.A. North; R.S. McDermott; K.N. Chi; M.R. Stockler; C.J. Sweeney; P.J. Meikle; L.G. Horvath
Validation of Prognostic and Predictive Models for Therapeutic Response in Patients Treated with [177Lu]Lu-PSMA-617 Versus Cabazitaxel for Metastatic Castration-resistant Prostate Cancer (TheraP): A Post Hoc Analysis from a Randomised, Open-label, Phase 2 Trial

[TheraP研究]：转移性去势抵抗性前列腺癌患者接受[177Lu]Lu-PSMA-617与卡巴他赛治疗疗效反应的预后和预测模型的验证——一项来自随机、开放标签、Ⅱ期临床试验的事后分析

EUROPEAN UROLOGY ONCOLOGY
IF9.3
2025-02-013
OAAI
Gafita, Andrei; Martin, Andrew J.; Emmett, Louise; Eiber, Matthias; Iravani, Amir; Fendler, Wolfgang P.; Buteau, James; Sandhu, Shahneen; Azad, Arun A.; Herrmann, Ken; Stockler, Martin R.; Davis, Ian D.; Hofman, Michael S.

研究方向

暂未获取到该数据
M
Martin R. Stockler
H 指数:65论文数:632被引数:2.0万
A
Andrew M. Scott
H 指数:95论文数:1,215被引数:3.6万
D
Damien Bolton
H 指数:58论文数:623被引数:1.3万
A
Arun Azad
H 指数:51论文数:521被引数:1.3万
C
Christopher J. Sweeney
H 指数:86论文数:820被引数:2.9万
M
Mark Frydenberg
H 指数:63论文数:404被引数:1.5万
A
Andrew Martin
H 指数:59论文数:473被引数:1.5万
N
Nathan Lawrentschuk
H 指数:71论文数:965被引数:2.1万
K
Karim Fizazi
H 指数:123论文数:1,539被引数:8.3万
A
Anthony M. Joshua
H 指数:70论文数:769被引数:3.1万